Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

[Our experience of the treatment with XELOX±Bevacizumab for unresectable advanced colorectal cancer].

Kashiwagi S, Maeda K, Fuyuhiro Y, Nagahara H, Kimura K, Amano R, Noda E, Kubo N, Tanaka H, Muguruma K, Yashiro M, Yamada N, Nakata B, Ohira M, Ishikawa T, Hirakawa K.

Gan To Kagaku Ryoho. 2011 Nov;38(12):1936-8. Japanese.

PMID:
22202244
2.

[Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)].

Sato A, Doi T, Boku N, Kato K, Komatsu Y, Yamaguchi K, Muro K, Hamamoto Y, Koizumi W, Mizunuma N, Takiuchi H.

Gan To Kagaku Ryoho. 2011 Apr;38(4):561-9. Japanese.

PMID:
21498982
3.

XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.

Rosati G, Avallone A, Aprile G, Butera A, Reggiardo G, Bilancia D.

Cancer Chemother Pharmacol. 2013 Jan;71(1):257-64. doi: 10.1007/s00280-012-2004-x. Epub 2012 Oct 26.

PMID:
23100174
4.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J.

J Clin Oncol. 2008 Apr 20;26(12):2013-9. doi: 10.1200/JCO.2007.14.9930. Erratum in: J Clin Oncol. 2008 Jun;26(18):3110. J Clin Oncol. 2009 Feb 1;27(4):653.

PMID:
18421054
5.

Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study.

Oba K, Matsuoka M, Satoh T, Muro K, Oriuchi N, Sakamoto J, Mishima H.

Jpn J Clin Oncol. 2011 Jan;41(1):134-8. doi: 10.1093/jjco/hyq165. Epub 2010 Sep 6.

PMID:
20819834
6.

Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer.

Larsen FO, Boisen MK, Fromm AL, Jensen BV.

Acta Oncol. 2012 Feb;51(2):231-3. doi: 10.3109/0284186X.2011.614637. Epub 2011 Sep 22.

PMID:
21936753
7.

A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.

Sehgal R, Lembersky BC, Rajasenan KK, Crandall TL, Balaban EP, Pinkerton RA, Kane P, Schmotzer A, Zeh H, Potter DM, Ramanathan RK.

Clin Colorectal Cancer. 2011 Jun;10(2):117-20. doi: 10.1016/j.clcc.2011.03.008. Epub 2011 Apr 28.

PMID:
21859564
8.

[Tolerability of XELOX in postoperative adjuvant chemotherapy for colorectal cancer].

Matsuda C, Danno K, Miyazaki S, Fujitani K, Kubota M, Kawada J, Takagi M, Fukui A, Iwase K, Tanaka Y.

Gan To Kagaku Ryoho. 2014 Jun;41(6):743-7. Japanese.

PMID:
25129086
9.

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L.

J Clin Oncol. 2008 Apr 20;26(12):2006-12. doi: 10.1200/JCO.2007.14.9898.

PMID:
18421053
10.

[Our experiences of XELOX + bevacizumab for two cases of metastatic sigmoid colon cancer].

Shioiri M, Kojima K, Yamamoto S, Watanabe Y, Mizutani M, Kamimura K.

Gan To Kagaku Ryoho. 2010 Nov;37(12):2511-3. Japanese.

PMID:
21224623
11.

Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.

Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F.

World J Gastroenterol. 2015 Jun 21;21(23):7281-8. doi: 10.3748/wjg.v21.i23.7281.

12.

Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy.

Inanc M, Duran AO, Karaca H, Berk V, Bozkurt O, Ozaslan E, Ozkan M.

Asian Pac J Cancer Prev. 2014;15(1):253-6.

13.

Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.

Kennecke H, Berry S, Wong R, Zhou C, Tankel K, Easaw J, Rao S, Post J, Hay J.

Eur J Cancer. 2012 Jan;48(1):37-45. doi: 10.1016/j.ejca.2011.05.016. Epub 2011 Jun 12.

PMID:
21664123
14.

[A case report of pathologically complete response of locally advanced rectal cancer after neoadjuvant chemoradiotherapy with XELOX and bevacizumab].

Miyazawa T, Ebe K, Fujita N, Koide N, Honma K, Ikarashi T.

Gan To Kagaku Ryoho. 2012 Jun;39(6):1001-3. Japanese.

PMID:
22705702
15.

Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients.

Coskun U, Buyukberber S, Yaman E, Uner A, Er O, Ozkan M, Dikilitas M, Oguz M, Yildiz R, B DY, Kaya AO, Benekli M.

Neoplasma. 2008;55(1):65-70.

PMID:
18190244
16.

[Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].

Lu GC, Fang F, Li DC.

Zhonghua Zhong Liu Za Zhi. 2010 Feb;32(2):152-5. Chinese.

PMID:
20403249
17.

Efficacy of oxaliplatin-based chemotherapy + bevacizumab as first-line treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trials.

Petrelli F, Coinu A, Ghilardi M, Cabiddu M, Zaniboni A, Barni S.

Am J Clin Oncol. 2015 Apr;38(2):227-33. doi: 10.1097/COC.0b013e3182a2d7b8. Review.

PMID:
25806713
18.

Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial).

Martoni AA, Pinto C, Di Fabio F, Lelli G, Rojas Llimpe FL, Gentile AL, Mutri V, Ballardini P, Giaquinta S, Piana E.

Eur J Cancer. 2006 Dec;42(18):3161-8. Epub 2006 Nov 13.

PMID:
17098421
19.

CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.

Petrioli R, Licchetta A, Roviello G, Pascucci A, Francini E, Bargagli G, Conca R, Miano ST, Marzocca G, Francini G; Multidisciplinary Oncology Group On Gastrointestinal Tumors.

Cancer Invest. 2012 Jan;30(1):65-71. doi: 10.3109/07357907.2011.629380.

PMID:
22236191
20.

A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer.

Zhi J, Chen E, Major P, Burns I, Robinson B, McKendrick J, Rittweger K, Abt M, Goldstein D.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1199-206. doi: 10.1007/s00280-011-1606-z. Epub 2011 Mar 16.

PMID:
21409383

Supplemental Content

Support Center